NASDAQ:AMGN - Amgen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $187.10 -2.98 (-1.57 %) (As of 12/18/2018 04:00 PM ET)Previous Close$190.08Today's Range$184.41 - $191.9452-Week Range$163.31 - $210.19Volume3.14 million shsAverage Volume3.46 million shsMarket Capitalization$122.39 billionP/E Ratio14.87Dividend Yield2.75%Beta1.41 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Receive AMGN News and Ratings via Email Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AMGN Previous Symbol CUSIP03116210 Webwww.amgen.com Phone805-447-1000 Debt Debt-to-Equity Ratio2.05 Current Ratio3.08 Quick Ratio2.84 Price-To-Earnings Trailing P/E Ratio14.87 Forward P/E Ratio13.14 P/E Growth2 Sales & Book Value Annual Sales$22.85 billion Price / Sales5.22 Cash Flow$15.0281 per share Price / Cash Flow12.45 Book Value$34.77 per share Price / Book5.38 Profitability EPS (Most Recent Fiscal Year)$12.58 Net Income$1.98 billion Net Margins9.44% Return on Equity54.14% Return on Assets13.27% Miscellaneous Employees20,800 Outstanding Shares637,220,000Market Cap$122.39 billion OptionableOptionable Amgen (NASDAQ:AMGN) Frequently Asked Questions What is Amgen's stock symbol? Amgen trades on the NASDAQ under the ticker symbol "AMGN." How often does Amgen pay dividends? What is the dividend yield for Amgen? Amgen announced a quarterly dividend on Friday, December 7th. Shareholders of record on Friday, February 15th will be given a dividend of $1.45 per share on Friday, March 8th. This represents a $5.80 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date is Thursday, February 14th. This is an increase from Amgen's previous quarterly dividend of $1.32. View Amgen's Dividend History. How will Amgen's stock buyback program work? Amgen declared that its Board of Directors has authorized a stock buyback plan on Friday, February 2nd 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its shares are undervalued. How were Amgen's earnings last quarter? Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.45 by $0.24. The medical research company had revenue of $5.90 billion for the quarter, compared to analysts' expectations of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company's revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 earnings per share. View Amgen's Earnings History. When is Amgen's next earnings date? Amgen is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Amgen. What guidance has Amgen issued on next quarter's earnings? Amgen issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided EPS guidance of $14.00-14.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.03. The company issued revenue guidance of $23.2-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.Amgen also updated its FY 2018 guidance to $14.00-14.25 EPS. What price target have analysts set for AMGN? 20 analysts have issued 12-month price targets for Amgen's shares. Their forecasts range from $179.00 to $232.00. On average, they expect Amgen's stock price to reach $204.5505 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price. View Analyst Price Targets for Amgen. What is the consensus analysts' recommendation for Amgen? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 12 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen. What are Wall Street analysts saying about Amgen stock? Here are some recent quotes from research analysts about Amgen stock: 1. Cantor Fitzgerald analysts commented, "We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk." (12/4/2018) 2. Mizuho analysts commented, ". After speaking with two physicians who treat between 50-100 patients per month for cellulite to discuss the market opportunity for ENDP’s CCH, we are increasingly more positive on the market opportunity for this product, if approved. We are still maintaining our Neutral rating because we think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than-expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock. Please contact your Cantor Fitzgerald representative for a replay of the call." (10/26/2018) 3. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions." (10/1/2018) 4. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018) Has Amgen been receiving favorable news coverage? Press coverage about AMGN stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Amgen earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the next several days. Who are some of Amgen's key competitors? Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO) and Acceleron Pharma (XLRN). Who are Amgen's key executives? Amgen's management team includes the folowing people: Mr. Robert A. Bradway, Chairman & CEO (Age 55)Mr. David W. Meline, Exec. VP & CFO (Age 61)Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)Dr. Sean E. Harper, Non-Exec. Officer (Age 55)Mr. Esteban Santos, Exec. VP of Operations (Age 50) Who are Amgen's major shareholders? Amgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.67%), Vanguard Group Inc (7.67%), BlackRock Inc. (7.10%), FMR LLC (5.62%), Capital Research Global Investors (5.40%) and Primecap Management Co. CA (3.26%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen. Which major investors are selling Amgen stock? AMGN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Clearbridge Investments LLC, The Manufacturers Life Insurance Company, Morgan Stanley, Mitsubishi UFJ Trust & Banking Corp, BlackRock Inc., Nordea Investment Management AB and Vanguard Group Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen. Which major investors are buying Amgen stock? AMGN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, FMR LLC, AQR Capital Management LLC, Candriam Luxembourg S.C.A., O Shaughnessy Asset Management LLC, Renaissance Technologies LLC and Bank of Montreal Can. View Insider Buying and Selling for Amgen. How do I buy shares of Amgen? Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amgen's stock price today? One share of AMGN stock can currently be purchased for approximately $185.74. How big of a company is Amgen? Amgen has a market capitalization of $122.39 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe. What is Amgen's official website? The official website for Amgen is http://www.amgen.com. How can I contact Amgen? Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected] MarketBeat Community Rating for Amgen (NASDAQ AMGN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 1,233 (Vote Outperform)Underperform Votes: 766 (Vote Underperform)Total Votes: 1,999MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What are the reasons investors use put options?